ADMA Biologics, Inc.
ADMA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $134,224 | $121,984 | $114,802 | $117,549 |
| % Growth | 10% | 6.3% | -2.3% | – |
| Cost of Goods Sold | $58,598 | $54,757 | $53,705 | $54,216 |
| Gross Profit | $75,626 | $67,227 | $61,097 | $63,333 |
| % Margin | 56.3% | 55.1% | 53.2% | 53.9% |
| R&D Expenses | $1,528 | $1,031 | $826 | $391 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $23,048 | $22,214 | $24,079 | $23,317 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $38 | $1,184 | $1,311 | $1,302 |
| Operating Expenses | $24,614 | $24,429 | $26,216 | $25,010 |
| Operating Income | $51,012 | $42,798 | $34,881 | $38,323 |
| % Margin | 38% | 35.1% | 30.4% | 32.6% |
| Other Income/Exp. Net | -$3,497 | -$2,701 | -$1,431 | -$3,610 |
| Pre-Tax Income | $47,515 | $40,097 | $33,450 | $34,713 |
| Tax Expense | $11,087 | $5,878 | $6,546 | -$77,183 |
| Net Income | $36,428 | $34,219 | $26,904 | $111,896 |
| % Margin | 27.1% | 28.1% | 23.4% | 95.2% |
| EPS | 0.15 | 0.14 | 0.11 | 0.47 |
| % Growth | 7.1% | 27.3% | -76.6% | – |
| EPS Diluted | 0.15 | 0.14 | 0.11 | 0.46 |
| Weighted Avg Shares Out | 238,603 | 241,491 | 237,775 | 236,434 |
| Weighted Avg Shares Out Dil | 244,664 | 248,608 | 244,676 | 245,901 |
| Supplemental Information | – | – | – | – |
| Interest Income | $376 | $400 | $608 | $598 |
| Interest Expense | $1,675 | $1,834 | $1,975 | $2,879 |
| Depreciation & Amortization | $2,023 | $2,058 | $1,969 | $1,944 |
| EBITDA | $51,213 | $43,989 | $37,394 | $39,536 |
| % Margin | 38.2% | 36.1% | 32.6% | 33.6% |